论文部分内容阅读
目的:评价低分子肝素对小儿肾病综合征患者的临床疗效。方法:选取2013年9月—2014年12月收治的小儿肾病综合征患者60例,将其分为治疗组(31例)与对照组(29例);治疗组患儿均给予低分子肝素治疗,对照组患儿均给予泼尼松治疗,比较两组患儿治疗前后凝血功能和生化功能各指标的变化情况。结果:治疗组患儿治疗后APTT、PT以及Fib等指标明显优于对照组(P<0.05);24 h尿蛋白定量、Scr、BUN以及TC等生化功能指标恢复情况均优于对照组(P<0.05);两组患儿均未出现不良反应。结论:采用低分子肝素治疗小儿肾病综合征患儿,可明显改善患儿生化指标和凝血功能,并增强治疗安全性。
Objective: To evaluate the clinical effect of low molecular weight heparin on children with nephrotic syndrome. Methods: Sixty children with nephrotic syndrome admitted from September 2013 to December 2014 were divided into treatment group (n = 31) and control group (n = 29). The treatment group was given low molecular weight heparin , The control group of children were given prednisone treatment, the two groups of children before and after treatment, coagulation and biochemical function of the changes in the indicators. Results: After treatment, the indexes of APTT, PT and Fib in the treatment group were significantly better than those in the control group (P <0.05). The levels of 24 h urinary protein, Scr, BUN and TC biochemical indexes recovered better than the control group <0.05). No adverse reactions occurred in both groups. Conclusion: The treatment of children with nephrotic syndrome with low molecular weight heparin can significantly improve children’s biochemical parameters and coagulation function, and enhance the safety of treatment.